Report shows growth in advanced therapeutics in Stockholm

A new report from Invest Stockholm on Advanced Therapeutics Manufacturing and Life Science in the Stockholm region showed that the sector has grown by 66% in the past four years.

Collaboration between local tech and pharma industries are expected to further enhance Stockholm’s competitiveness and growth in the future.

Both global companies and specialist start-ups can be found in the Stockholm-Uppsala region, and the city is becoming recognised as somewhere for firms looking to establish and expand their advanced therapeutics manufacturing facilities.

“The report makes it very clear that the thriving Stockholm-Uppsala life science cluster benefits hugely from a long tradition of collaboration between the public sector, industry and academia. In the region’s many hubs for innovation and entrepreneurship, transparent structures and a sense of common purpose enable local governments, life science companies and universities to work together to forge a brighter future,” said Ylva Hultman, Head of Life Science at Invest Stockholm.

The report suggests the sector’s success is owing to factors such as: diversity, stable operating conditions, high quality physical infrastructure, environmental credentials and an attractive business environment.

Strong growth in the life science sector can be explained in part by an increase in demand due to the ongoing pandemic, but the sector had already seen 28% growth in 2019.

Exports for the sector are valued at US$13.6 billion and make up 10% of the total value of Sweden’s exports.

For the European biotechnology sector in 2020, there were 74 listings for Nasdaq Nordic, compared with 43 for London and 12 for Switzerland. In the coming decade, it is predicted that Sweden and the Stockholm region will be among the best places in the world in which to invest.

Download the report to learn more about the work being done to fuel the sector. The report features a detailed overview of the sector by Professor Johan Rockberg from the Royal Institute of Technology, and Catarina Flyborg, Vice President of Cell and Gene Therapy at Cytiva. It also includes case studies from life science companies AstraZeneca, Cambrex, Cytiva, Galderma, Pharmadule Morimatsu, and Valneva, all based in the Stockholm region.

Image Credit: Micael Widell

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free